# US 2021/0231665 A1 · Detection methods employing hcv core lipid and dna binding domain monoclonal antibodies

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2021/0231665 A1
- Document ID: US20210231665A1
- Status: Published application
- Kind: A1
- Application number: 17/231,782
- Filed: 2021-04-15
- Published: 2021-07-29
- Earliest claimed: 2013-03-14
- Assignees: Abbott Laboratories
- Applicants: Abbott Laboratories
- Inventors: Robert Ziemann; April Ahlberg; David Hawksworth; Bryan Tieman; A. Scott Muerhoff; Christopher Marohnic; Kathy Otis
- Web page: https://patentgrep.com/patent/US20210231665A1

## CPC

- G01N 33/5767: {non-A, non-B hepatitis}
- C07K 16/118: Hepatitis C virus; GB virus C [GBV-C]
- C07K 2317/34: Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
- C07K 2317/56: variable (Fv) region, i.e. VH and/or VL
- C07K 2317/92: Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
- G01N 2333/186: Hepatitis C; Hepatitis NANB
- G01N 2469/10: Detection of antigens from microorganism in sample from host
- G01N 2800/52: Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)

## Abstract

The present disclosure provides detection methods employing HCV core lipid binding domain and DNA binding domain monoclonal antibodies. In certain embodiments, the lipid binding domain monoclonal antibody recognizes an epitope in amino acids 141 to 161 of HCV core protein.

## Claims

### Claim 1

A method for the detection of HCV protein in a test sample comprising:
(i) contacting a test sample suspected of containing HCV with a first monoclonal antibody, or antigen-binding portion thereof, which specifically binds to an epitope in the DNA binding domain of an HCV core protein to form a first complex between said first monoclonal antibody, or antigen-binding fragment thereof, and said HCV core protein located within said test sample;
(ii) contacting the first complex formed in step (i) with a second monoclonal antibody comprising a heavy chain variable domain amino acid sequence of SEQ ID NO: 100 and a light chain variable domain amino acid sequence of SEQ ID NO: 382 and/or a third monoclonal antibody comprising a heavy chain variable domain amino acid sequence of SEQ ID NO: 44 and a light chain variable domain amino acid sequence of SEQ ID NO: 342, or an antigen-binding fragment thereof, to form a second complex between the second monoclonal antibody and/or the third monoclonal antibody, or antigen-binding fragment thereof, and said first complex formed in step (i), and
(iii) detecting the second complex formed in step (ii).

### Claim 2 (depends on 1)

The method of claim 1, wherein the second monoclonal antibody and/or third monoclonal antibody, or antigen-binding fragment thereof, comprises a detectable label, and wherein detecting the second complex in step (iii) comprises detecting a signal from the label.

### Claim 3 (depends on 1)

The method of claim 1, which comprises contacting the first complex with the second monoclonal antibody and the third monoclonal antibody.

### Claim 4 (depends on 2)

The method of claim 2, wherein the detectable label is a fluorescent label or an acridinium label.

### Claim 5 (depends on 1)

The method of claim 1, wherein the first monoclonal antibody is bound to a solid phase.

### Claim 6

A monoclonal antibody comprising a heavy chain variable domain amino acid sequence of SEQ ID NO: 100 and a light chain variable domain amino acid sequence of SEQ ID NO: 382, which specifically binds to the lipid binding domain of the HCV core antigen.

### Claim 7 (depends on 6)

A composition comprising the monoclonal antibody of claim 6 and a pharmaceutically acceptable carrier.

### Claim 8

A monoclonal antibody comprising a heavy chain variable domain amino acid sequence of SEQ ID NO: 44 and a light chain variable domain amino acid sequence of SEQ ID NO: 342, which specifically binds to the lipid binding domain of the HCV core antigen.

### Claim 9 (depends on 8)

A composition comprising the monoclonal antibody of claim 8 and a pharmaceutically acceptable carrier.
